Cytokine Release Syndrome (CRS) is a potentially life-threatening systemic inflammatory response triggered by widespread immune activation, which results in abnormally high concentrations of systemic cytokines. In oncology, it is most frequently associated with immunotherapies such as blinatumomab and CAR T-cell therapies like tisagenlecleucel.
Clinical Presentation
Symptoms of CRS result from a “cytokine storm” and can affect multiple organ systems:
- Constitutional: High fevers, rigors, fatigue, malaise, and myalgias.
- Cardiovascular: Hypotension, tachycardia, arrhythmias, and capillary leak.
- Respiratory: Tachypnea, hypoxia, and pulmonary infiltrates.
- Organ Dysfunction: Elevated liver function tests (LFTs), hyperbilirubinemia, and acute kidney injury.
Pathophysiology and Management
- Key Driver: Interleukin-6 (IL-6) is often significantly upregulated during these states.
- Tocilizumab: This anti-IL-6 receptor antibody is the standard treatment to block the inflammatory cascade without necessarily destroying the therapeutic T-cells.
- Steroids: Dexamethasone or methylprednisolone are reserved for severe or refractory cases to avoid interfering with the efficacy of the cellular therapy.
- Monitoring: Management is based on the ASTCT Consensus Grading (Grades 1–4), which dictates when to escalate from supportive care to tocilizumab or intensive care.
Grading (ASTCT Criteria)
- Grade 1: Fever ≥38°C
- Grade 2: Fever + hypotension responsive to fluids or low-flow oxygen
- Grade 3: Hypotension requiring vasopressors or higher-flow oxygen
- Grade 4: Life-threatening (ventilation, multiple vasopressors)
- Grade 5: Death
Management
Supportive Care
- IV fluids, oxygen, vasopressors as needed
- ICU support in severe cases
- Rule out sepsis (can mimic)
Pharmacologic
- Tocilizumab (IL-6 receptor antagonist):
- First-line treatment (especially Grade ≥2)
- 8 mg/kg IV (max 800 mg); can repeat every 8 hours (max 4 doses)
- Corticosteroids (e.g., dexamethasone, methylprednisolone):
- For Grade ≥2, not responsive to tocilizumab
- Especially important in CAR-T–associated neurotoxicity
Monitoring
- Vital signs: continuous in at-risk patients
- CBC, CRP, ferritin, IL-6 (if available)
- Liver and renal function, coags
- Neurologic assessment (due to risk of immune effector cell-associated neurotoxicity syndrome [ICANS])
Prevention/Prophylaxis
- Premedication: acetaminophen, antihistamines ± corticosteroids before therapy (especially with bispecifics)
- Use of step-up dosing (e.g., with blinatumomab) to reduce risk
- CRS risk stratification protocols for CAR-T patients
Key Notes for Oncology Pharmacist
- Ensure tocilizumab is available and accessible in centers giving CAR-T or bispecifics
- Educate staff on early recognition
- Coordinate care closely with ICU/critical care teams in high-grade CRS
- Do not delay tocilizumab if CRS is suspected